![Jesper Brandgaard](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jesper Brandgaard
Président chez
Novo Nordisk Region Japan & Korea A/S
Profil
Jesper Brandgaard currently works at LEO Pharma A, as Chairman from 2021, Leo Pharma, Inc., as Chairman from 2021, Novo Nordisk Invest 2 A, as Chairman, Novo Nordisk Health Care AG, as Chairman-Supervisory Board, Novo Nordisk Region Japan & Korea A, as Chairman, Novo Nordisk Gsc Holding A, as Chairman, Novo Nordisk Pharmaceuticals A, as Chairman, Novo Nordisk Region China A, as Chairman, Novo Nordisk Region North America Ii A, as Chairman, William Demant Invest A, as Vice Chairman from 2019, Chr.
Hansen A, as Independent Director from 2017, Novo Nordisk Holding Ltd., as Director, Novo Nordisk China Pharmaceuticals Co. Ltd., as Director, William Demant Fonden, as Director from 2019, VækstPartner Kapital ApS, as Director from 2019, and Novo Nordisk Haemophilia Foundation, as Member.
Mr. Brandgaard also formerly worked at SimCorp A, as Chairman from 2008 to 2019, NNIT A, as Chairman from 2002 to 2017, Novo Nordisk Invest 1 A, as Chairman, LEO Pharma NV, as Chairman, Novo Nordisk Region AAMEO & LATAM A, as Chairman, NNE Pharmaplan A, as Chairman, Novo Nordisk Region Europe A, as Chairman, Novonesis A, as Vice Chairman, NNIT A, as Director in 2001, Chr.
Hansen Holding A, as Independent Director from 2017 to 2018, SciClone Pharmaceuticals (Holdings) Ltd., as Non-Executive Director, and Novo Nordisk A, as EVP-Biopharm & Legal Affairs from 2018 to 2019.
Mr. Brandgaard received his graduate degree in 1990 from Copenhagen Business School and Masters Business Admin degree in 1995 from Copenhagen Business School.
Postes actifs de Jesper Brandgaard
| Sociétés | Poste | Début |
|---|---|---|
Novo Nordisk Region Japan & Korea A/S
 Novo Nordisk Region Japan & Korea A/S Financial ConglomeratesFinance Functions as an investment holding company | Président | - |
Novo Nordisk Gsc Holding A/S
 Novo Nordisk Gsc Holding A/S Financial ConglomeratesFinance Functions as an investment holding company | Président | - |
Novo Nordisk Pharmaceuticals A/S
 Novo Nordisk Pharmaceuticals A/S Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals | Président | - |
Novo Nordisk Invest 2 A/S | Président | - |
Novo Nordisk Region China A/S
 Novo Nordisk Region China A/S MiscellaneousMiscellaneous Functions as an investment holding company | Président | - |
Novo Nordisk Region North America Ii A/S | Président | - |
Novo Nordisk Holding Ltd. | Directeur/Membre du Conseil | - |
Novo Nordisk China Pharmaceuticals Co. Ltd.
 Novo Nordisk China Pharmaceuticals Co. Ltd. Pharmaceuticals: MajorHealth Technology Manufactures diabetes and obesity treatment products | Directeur/Membre du Conseil | - |
Chr. Hansen A/S
 Chr. Hansen A/S Pharmaceuticals: OtherHealth Technology Manufactures natural food ingredient solutions | Directeur/Membre du Conseil | 01/01/2017 |
| ░░░░ ░░░░░░░ ░░░░░░░░░░░ ░░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Anciens postes connus de Jesper Brandgaard
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░ ░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
Formation de Jesper Brandgaard
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
68
Relations au 1er degré
27
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 27 |
|---|---|
Novo Nordisk A/S
 Novo Nordisk A/S Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products for diabetes care | Health Technology |
SimCorp A/S
 SimCorp A/S Packaged SoftwareTechnology Services Develops investment management platform | Technology Services |
Chr. Hansen A/S
Chr. Hansen A/S Pharmaceuticals: OtherHealth Technology Manufactures natural food ingredient solutions | Health Technology |
William Demant Invest A/S
 William Demant Invest A/S Investment ManagersFinance WDI is an active manager which provides equity and debt funding for growth-stage capital requirements, and buyout transactions. The firm targets companies operating in the health services and consumer durables sector, and industries such as biotechnology, pharmaceuticals, electronic equipment, and real estate. WGI invests in both public and private companies from Denmark and Europe, and looks to take both minority and majority stake positions in its investments, as well as a seat on the board. | Finance |
Copenhagen Business School
 Copenhagen Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
LEO Pharma A/S
 LEO Pharma A/S Medical/Nursing ServicesHealth Services Provides dermatology services | Health Services |
Leo Pharma, Inc.
 Leo Pharma, Inc. Drugstore ChainsRetail Trade Wholesales drugs and sundries | Retail Trade |
NNIT A/S
 NNIT A/S Information Technology ServicesTechnology Services Provides digital transformation solutions to international life sciences companies | Technology Services |
Chr. Hansen Holding A/S
 Chr. Hansen Holding A/S Food: Specialty/CandyConsumer Non-Durables Manufactures food cultures, enzymes and nutrition products | Consumer Non-Durables |
Novo Nordisk Invest 1 A/S | |
LEO Pharma NV
 LEO Pharma NV Medical/Nursing ServicesHealth Services Provides dermatology services | Health Services |
Novo Nordisk Invest 2 A/S | |
Novo Nordisk Region Aameo & Latam A/S
 Novo Nordisk Region Aameo & Latam A/S Financial ConglomeratesFinance Functions as an investment holding company | Finance |
NNE Pharmaplan A/S
 NNE Pharmaplan A/S Pharmaceuticals: MajorHealth Technology Produces pharmaceutical products | Health Technology |
Novo Nordisk Region Europe A/S
 Novo Nordisk Region Europe A/S Financial ConglomeratesFinance Functions as an investment holding company | Finance |
William Demant Fonden
 William Demant Fonden Investment Trusts/Mutual FundsMiscellaneous Functions as a foundation or endowment | Miscellaneous |
Novo Nordisk Haemophilia Foundation | |
Novo Nordisk Health Care AG
 Novo Nordisk Health Care AG Pharmaceuticals: MajorHealth Technology Develops, manufactures, markets and distributes pharmaceutical products | Health Technology |
Novo Nordisk Region Japan & Korea A/S
Novo Nordisk Region Japan & Korea A/S Financial ConglomeratesFinance Functions as an investment holding company | Finance |
Novo Nordisk Gsc Holding A/S
Novo Nordisk Gsc Holding A/S Financial ConglomeratesFinance Functions as an investment holding company | Finance |
Novo Nordisk Pharmaceuticals A/S
Novo Nordisk Pharmaceuticals A/S Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals | Health Technology |
Novo Nordisk Region China A/S
Novo Nordisk Region China A/S MiscellaneousMiscellaneous Functions as an investment holding company | Miscellaneous |
Novo Nordisk Region North America Ii A/S | |
Novo Nordisk Holding Ltd. | |
Novo Nordisk China Pharmaceuticals Co. Ltd.
Novo Nordisk China Pharmaceuticals Co. Ltd. Pharmaceuticals: MajorHealth Technology Manufactures diabetes and obesity treatment products | Health Technology |
VækstPartner Kapital ApS
 VækstPartner Kapital ApS Investment ManagersFinance VækstPartner is an active manager and contributes both with growth capital and management support. The firm provides equity investments in companies with revenues between DKK 10 and 75 million. It focuses on small Danish technology-based companies operating in industries such as technology services, packaged software, and online platforms. The firm takes both minority and majority stake positions, as well as a seat on the board. | Finance |
SciClone Pharmaceuticals (Holdings) Ltd.
 SciClone Pharmaceuticals (Holdings) Ltd. Pharmaceuticals: MajorHealth Technology Manufactures and markets immune and oncology pharmaceutical products | Health Technology |
